Upstream Bio, Inc. has attracted attention with a recent filing revealing that FMR LLC holds a significant stake in the company. The latest Schedule 13G/A filing, dated November 6, 2026, indicates that FMR LLC beneficially owns approximately 3,793,955 shares, which amounts to about 6.9% of Upstream Bio's common stock. This development is noteworthy as it reflects growing investor interest in the pharmaceutical preparations sector.

Background

Upstream Bio, Inc. is a company engaged in the pharmaceutical preparations industry, classified under the SIC code 2834. The company trades under the ticker UPB on the Nasdaq exchange. Recent filings include a Schedule 13G/A on November 6, 2026, and a Schedule 13G/A on October 29, 2026, indicating ongoing disclosures regarding ownership stakes.

What the Filing Says

The filing reveals that FMR LLC, a Delaware-based investment firm, has reported its beneficial ownership of 3,793,955 shares of Upstream Bio, representing 6.9% of the company's common stock. Abigail P. Johnson, a key figure at FMR LLC, is also noted as a beneficial owner of the same number of shares.

Impact

This disclosure may impact various stakeholders, including current shareholders and potential investors, as it reflects a significant investment by a well-known asset management firm. The filing also mentions that the Johnson family, through their ownership of voting common shares, may form a controlling group with respect to FMR LLC.

What's Next

The filing does not say what happens next.